COVID-19 has brought disease and mortality at levels not seen from a respiratory virus for over 100 years. Immune responses to this virus, which can infect several different tissues, are poorly understood, including the role of antibodies in resolving the infection. In March 2020, we reoriented our lab to develop Enzyme-Linked ImmunoSorbent Assays (ELISA) for human antibody isotypes IgM, IgG and IgA produced in response to the SARS-CoV-2 spike protein. To date we have analyzed samples from 114 patients, including both PCR positive and PCR negative individuals.